Assessment Tool for Hospital Admissions Related to Medications (AT-HARM10) - development and validation

Al-Sammak Y1, Kempen T2,3, Gillespie U4
1Department of Pharmaceutical Bioscience, Uppsala University, Sweden
2Uppsala University Hospital, Uppsala, Sweden 3Department of Medical Sciences, Uppsala University, Sweden

Introduction:
MedBridge, a study with the aim to evaluate the effects of medication reviews, performed by hospital based clinical pharmacists on elderly patients' health-care consumption, started in February 2017. One outcome measure will be the prevalence of drug-related (re)admissions (DRAs) to hospital. (www.akademiska.se/medbridge) The process of identifying DRAs is inevitably subjective and often time-consuming. Therefore, quick, reliable and standardized methods are warranted.

Aim:
The aim of this study was to develop and validate a practical/feasible tool to identify possible DRA's.

Methods:
The study was undertaken in three steps;
(i) Survey of the field to identify existing tools that met with the predefined requirements
(ii) The development of a tool including tests of content validity (CV) and feasibility resulting in iterative changes
(iii) Assessment of the final product's criterion-related validity (CRV) and inter-rater reliability (IRR).

A tool consisting of Yes/no questions was developed based on existing methods in literature used to identify DRAs. IRR and CRV was determined using four couples, consisting of clinical pharmacists and advanced pharmacy students, separately applying the tool to 50 + 50 hospital admissions. The same admissions had previously undergone assessments by two experienced clinicians/experts, making up the “Gold Standard”. The results were analyzed statistically using Cohen's kappa and Fleiss kappa for IRR, and sensitivity and specificity for CRV.

Results:
The final tool, AT-HARM10, consisted of ten yes/no questions to identify unlikely and possibly medication-related admissions. The tool showed sufficient CV and feasibility and had a moderate to substantial IRR with Cohen's kappa values ranging between 0.45 - 0.75 and Fleiss kappa values of 0.46 and 0.58.

For the CRV, the sensitivity and specificity ranged between 68 - 82 % and 64 - 89 % respectively. Both the gold standard and the AT-HARM10 assessors identified approximately 50% of the admissions as DRAs.

Conclusion:
The validity and reliability of AT-HARM10 was found to be satisfactory. Advanced pharmacy students showed sufficient competence to use the tool when provided with adequate instructions and training.